http://emedicine.medscape.

com/article/976034-overviewReferences
Serrano AG, Ryan M, Weaver TE, et al. Critical structure-function determinants within the N-terminal
region of pulmonary surfactant protein SP-B. Biophys J. 2006 Jan 1. 90(1):238-49. [Medline].
Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant
deficiency. N Engl J Med. 2004 Mar 25. 350(13):1296-303. [Medline].
Gerten KA, Coonrod DV, Bay RC, et al. Cesarean delivery and respiratory distress syndrome: does labor
make a difference?. Am J Obstet Gynecol. 2005 Sep. 193(3 Pt 2):1061-4. [Medline].
Qiu X, Lee SK, Tan K, et al. Comparison of Singleton and Multiple-Birth Outcomes of Infants Born at or
Before 32 Weeks Gestation. Obstetrics and Gynecology. February 2008. 111:365-371. [Medline].
Hintz SR, Van Meurs KP, Perritt R, et al. Neurodevelopmental Outcomes of Premature Infants with Severe
Respiratory Failure Enrolled in a Randomized Controlled Trial of Inhaled Nitric Oxide. Journal of
Pediatrics. July 2007. 151:e1-3. [Medline].
Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in Neonatal Morbidity and Mortality for Very Low
Birthweight Infants. American Journal of Obstetrics and Gynecology. February 2007. 147:e1-e8. [Medline].
Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against
fungal colonization and infection in preterm infants. N Engl J Med. 2001 Dec 6. 345(23):1660-6.
[Medline].
Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low
birth weight infants. Cochrance Database Syst Rev. Jan 2008. 23:CD003481. [Medline].
Su PH, Chen JY. Inhaled Nitric Oxide in the Management of Preterm Infants with Severe Respiratory
Failure. Journal of Perinatology. February 2008. 28:112-116. [Medline].
Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for
retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2011 Dec 30. [Medline].
Sun H, Zhou Y, Xiong H, et al. Prognosis of Very Preterm Infants with Severe Respiratory Distress
Syndrome Receiving Mechanical Ventilation. Lung. 2015 Jan 13. [Medline].
Billman GF, Hughes AB, Dudell GG, et al. Clinical performance of an in-line, ex vivo point-of-care
monitor: a multicenter study. Clin Chem. 2002 Nov. 48(11):2030-43. [Medline].
Gupta S, Sinha S, Tin W, et al. A randomized controlled trial of post-extubation bubble continuous positive
airway pressure versus Infant Flow Driver continuous positive airway pressure in preterm infants with
respiratory distress syndrome. Journal of Pediatrics. May 2009. 154:645-650. [Medline].
De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and Pressure Sources for Administration of Nasal
Continuous Positive Airway Pressure (NCPAP) in Preterm Neonates (Review). The Cochrane
Collaboration. [Medline].
Patry C, Hien S, Demirakca S, et al. Adjunctive Therapies for Treatment of Severe Respiratory Failure in
Newborns. Klin Padiatr. 2015 Jan. 227(1):28-32. [Medline].
Crowther CA, Haslam RR, Hiller JE, et al. Neonatal respiratory distress syndrome after repeat exposure to
antenatal corticosteroids: a randomised controlled trial. Lancet. June 2006. 367:1913-1919. [Medline].
Doyle LW, Davis PG, Morley CJ, et al. Outcome at 2 Years of Age of Infants from the DART Study: A
Multicenter, International, Randomized, Controlled Trial of Low-Dose Dexamethasonef. Pediatrics. April
2007. 119:716-721. [Medline].

Lin YJ, Lin CH, Wu JM, et al. The effects of early postnatal dexamethasone therapy on pulmonary outcome
in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatr. 2005
Mar. 94(3):310-6. [Medline].
Peaceman AM, Bajaj K, Kumar P, et al. The interval between a single course of antenatal steroids and
delivery and its association with neonatal outcomes. Am J Obstet Gynecol. 2005 Sep. 193(3 Pt 2):1165-9.
[Medline].
Pesonen AK, Raikkonen K, Lano A, et al. Antenatal betamethasone and fetal growth in prematurely born
children: implications for temperament traits at the age of 2 years. Pediatrics. 2009 Jan. 123(1):e31-7.
[Medline].
Ring AM, Garland JS, Stafeil BR, et al. The effect of a prolonged time interval between antenatal
corticosteroid administration and delivery on outcomes in preterm neonates: a cohort study. Am J Obstet
Gynecol. May 2007. 196:1-6. [Medline].
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of
preterm birth. Cochrane Database Syst Rev. July 2006. 3:CD004454. [Medline].
Wapner RJ, Sorokin Y, Thom EA, et al. Single versus weekly courses of antenatal corticosteroids:
evaluation of safety and efficacy. Am J Obstet Gynecol. 2006. 195:633-642. [Medline].
Murphy KE, Hannah ME, Willan AR, et al. Multiple courses of antenatal corticosteroids for preterm birth
(MACS): a randomised controlled trial. Lancet. Dec 2008. 372:2143-2151. [Medline].
Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing
respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011 Apr 12. 342:d1696.
[Medline]. [Full Text].
Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids.
New England Journal of Medicine. 2007. 357:1190-1198. [Medline].
Crowther CA, Doyle LW, Haslam RR, et al. Outcomes at 2 years of age after repeat doses of antenatal
corticosteroids. N Engl J Med. 2007. 357:1179-1189. [Medline].
Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and
neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA. 2011 Dec 7.
306(21):2348-58. [Medline].
Engle WA, The Committee on Fetus and Newborn. Surfactant-Replacement Therapy for Respiratory
Distress in the Preterm and Term Neonate. Pediatrics. February 2008. 212:419-432. [Medline].
Katz LA, Klein JM. Repeat Surfactant Therapy fro Postsurfactant Slump. Journal of Perinatology. May
2006. 26:414-422. [Medline].
Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, et al. Very early surfactant without
mandatory ventilation in premature infants treated with early continuous positive airway pressure: a
randomized, controlled trial. Pediatrics. 2009 Jan. 123(1):137-42. [Medline].
Turker G, Koksal N. Complement 4 levels as early predictors of poor response to surfactant therapy in
respiratory distress syndrome. Am J Perinatol. 2005 Apr. 22(3):149-54. [Medline].
Fuchs H, Lindner W, Leiprecht A, Mendler MR, Hummler HD. Predictors of early nasal CPAP failure and
effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of 1111Arch
Dis Child Fetal Neonatal Ed</i>. 2011 Sep. 96(5):F343-7. [Medline].

Stevens TP, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs selective
surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress
syndrome. Cochrane Database Syst Rev. 2004. CD003063. [Medline].
Reininger A, Khalak R, Kendig JW, et al. Surfactant administration by transient intubation in infants 29 to
35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical
ventilation: a randomized controlled trial. J Perinatol. 2005 Nov. 25(11):703-8. [Medline].
Kahn DJ, Courtney SE, Steele AM, Habib RH. Unpredictability of delivered bubble nasal continuous
positive airway pressure: role of bias flow magnitude and nares-prong air leaks. Pediatr Res. Sept 2007.
62:343-347. [Medline].
Notter RH. Lung surfactants: Basic science and clinical applications. Lung Biology in Health and Disease.
2000. Vol 149: 7-344.
Kresch MJ, Lin WH, Thrall RS. Surfactant replacement therapy. Thorax. 1996 Nov. 51(11):1137-54.
[Medline].
Laughon M, Bose C, Moya F, et al. A Pilot Randomized, Controlled Trial of Later Treatment With a
Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. Pediatrics.
2009. 123:89-96. [Medline].
Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in
neonatal respiratory distress syndrome. Acta Paediatr. 2005 Jun. 94(6):779-84. [Medline].
Moya F, Maturana A. Animal-Derived Surfactants Versus Past and Current Synthetic Surfactants: Current
Status. Clinics in Perinatoloty. 2007. 34:145-177. [Medline].
Moya F, Sinha S, Gadzinowski J, et al. One-Year Follow-up of Very Preterm Infants who Received
Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized,
Controlled Trials. Pediatrics. June 2007. 119:e1361-e1370. [Medline].
Pfister RH, Soll R, Wiswell TE. Protein Containing Synthetic Surfactant Versus Animal-Derived Surfactant
Extract for the Prevention and Treatment of Respiratory Distress Syndrome (Review). The Cochrance
Collaboration. October 2007. 4:[Medline].
Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A Multicenter, Randomized, Controlled Trial of
Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress
Syndrome. Pediatrics. April 2005. 115:1030-1038. [Medline].
Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A. A multicenter, randomized,
masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of
respiratory distress syndrome among very preterm infants. Pediatrics. 2005 Apr. 115(4):1018-29.
[Medline].
Kinniry P, Pick J, Stephens S, et al. KL4-Surfactant Prevents Hyperoxic and LPS-Induced Lung Injury in
Mice. Pediatric Pulmonology. October 2006. 41:916-928. [Medline].
Gregory GA, Kitterman JA, Phibbs RH, et al. Treatment of the idiopathic respiratory-distress syndrome
with continuous positive airway pressure. N Engl J Med. 1971 Jun 17. 284(24):1333-40. [Medline].
Ammari A, Suri M, Milisavljevic V, et al. Variables associated with the early failure of nasal CPAP in very
low birth weight infants. J Pediatr. 2005 Sep. 147(3):341-7. [Medline].

Murray PG, Stewart MJ. Use of Nasal Continuous Positive Airway Pressure During Retrieval of Neonates
With Acute Respiratory Distress. Pediatrics. March 2008. 121:e754-e758. [Medline].
Wells DA, Gillies D, Fitzgerald DA. Positioning for acute respiratory distress in hospitalised infants and
children. Cochrane Database Syst Rev. 2005. CD003645. [Medline].
Stack JA, Jalaludin B. Developmental Outcomes at the Age of Two Years for Very Premature Babies
Managed with Nasal Prong Continuous Positive Airway Pressure. Journal of Paediatrics and Child Health.
June 2007. 43:480-485. [Medline].
Subramaniam P, Henderson-Smart DJ, Davis PG. Prophylactic nasal continuous positive airways pressure
for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. July 2005.
20:CD001243. [Medline].
Booth C, Premkumar MH, Yannoulis A, et al. Sustainable use of continuous positive airway pressure in
extremely preterm infants during the first week after delivery. Arch Dis Child Fetal Neonatal Ed. Nov 2006.
91:398-402. [Medline]. [Full Text].
Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. New
England Journal of Medicine. Feb 2008. 358:700-708. [Medline].
Narendran V, Donovan E, Hoath S, et al. Early Bubble CPAP and Outcomes in ELBW Preterm Infants.
Journal of Perinatology. May 2003. 23:195-199. [Medline].
Lampland AL, Plumm B, Worwa C, Meyers P, Mammel MC. Bi-level CPAP does not improve gas
exchange when compared with conventional CPAP for the treatment of neonates recovering from
respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 2015 Jan. 100(1):F31-4. [Medline].
Armfield M, West G. Use of Vapotherm for respiratory support with neonates. Paediatr Nurs. 2009 Feb.
21(1):27-30. [Medline].
Holleman-Duray D, Kaupie D, Weiss MG. Heated humidified high-flow nasal cannula: use and a neonatal
early extubation protocol. Journal of Perinatology. 2007. 27:776-781. [Medline].
Kirby R, Robison E, Schulz J, DeLemos RA. Continuous-flow ventilation as an alternative to assisted or
controlled ventilation in infants. Anesth Analg. 1972 Nov-Dec. 51(6):871-5. [Medline].
D'Angio CT, Chess PR, Kovacs SJ, et al. Pressure-regulated volume control ventilation vs synchronized
intermittent mandatory ventilation for very low-birth-weight infants: a randomized controlled trial. Arch
Pediatr Adolesc Med. 2005 Sep. 159(9):868-75. [Medline].
Truffert P, Paris-Llado J, Escande B, et al. Neuromotor Outcome at 2 Years of Very Preterm Infants Who
Were Treated with High-Frequency Oscillatory Ventilation or Conventional Ventilation for Neonatal
Respiratory Distress Syndrome. Pediatrics. 2007. 119:e860-e865. [Medline].
Field D, Elbourne D, Truesdale A, et al. Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory
Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: the INNOVO
multicentre randomised controlled trial. Pediatrics. April 2005. 115:926-936. [Medline].
Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr. 2007 Jul. 151(1):10-5.
[Medline].
Schreiber MD, Marks JD. No definitive recommendation for iNO in preterm infants. J Pediatr. 2006 Jul.
149(1):146-7; author reply 147. [Medline].

Van Meurs KP, Hintz SR, Ehrenkranz RA, et al. Inhaled nitric oxide in infants >1500 g and 1111111J
Perinatol</i>. 2007 Jun. 27(6):347-52. [Medline].
Ballard RA, Truog WE, Cnaan A, et al. Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical
Ventilation. New England Journal of Medicine. July 2006. 355:343-353. [Medline].
Kinsella JP. Inhaled nitric oxide in the term newborn. Early Hum Dev. 2008 Nov. 84(11):709-16.
[Medline].
Ahmed SJ, Rich W, Finer NN. The effect of averaging time on oximetry values in the premature infant.
Pediatrics. 2010 Jan. 125(1):e115-21. [Medline].
Claure N, Bancalari E, D'Ugard C, et al. Multicenter crossover study of automated control of inspired
oxygen in ventilated preterm infants. Pediatrics. 2011 Jan. 127(1):e76-83. [Medline].
Courtney SE, Kahn DJ, Singh R, Habib RH. Bubble and ventilator-derived nasal continuous positive
airway pressure in premature infants: work of breathing and gas exchange. J Perinatol. 2011 Jan. 31(1):4450. [Medline].
Dumpa V, Northrup V, Bhandari V. Type and timing of ventilation in the first postnatal week is associated
with bronchopulmonary dysplasia/death. Am J Perinatol. 2011 Apr. 28(4):321-30. [Medline].
Finer NN, Carlo WA, Walsh MC, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J
Med. 2010 May 27. 362(21):1970-9. [Medline]. [Full Text].
Jatana KR, Oplatek A, Stein M, Phillips G, Kang DR, Elmaraghy CA. Effects of nasal continuous positive
airway pressure and cannula use in the neonatal intensive care unit setting. Arch Otolaryngol Head Neck
Surg. 2010 Mar. 136(3):287-91. [Medline].
Kugelman A, Feferkorn I, Riskin A, Chistyakov I, Kaufman B, Bader D. Nasal intermittent mandatory
ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a
randomized, controlled, prospective study. J Pediatr. 2007 May. 150(5):521-6, 526.e1. [Medline].
Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB. Nasal CPAP or intubation at birth for
very preterm infants. N Engl J Med. 2008 Feb 14. 358(7):700-8. [Medline].
Singh J, Sinha SK, Alsop E, Gupta S, Mishra A, Donn SM. Long term follow-up of very low birthweight
infants from a neonatal volume versus pressure mechanical ventilation trial. Arch Dis Child Fetal Neonatal
Ed. 2009 Sep. 94(5):F360-2. [Medline].
Walsh MC, Hibbs AM, Martin CR, et al. Two-year neurodevelopmental outcomes of ventilated preterm
infants treated with inhaled nitric oxide. J Pediatr. 2010 Apr. 156(4):556-61.e1. [Medline]. [Full Text].